The Orphan Drug Act of 1983

The Orphan Drug Act became law on Jan. 4, 1983, as Public Law 97-414¹. Its opening findings named Huntington's disease, myoclonus, ALS, Tourette syndrome and muscular dystrophy as conditions that affect “such small numbers of individuals” that a company developing a drug for one “may reasonably expect the drug to generate relatively small sales in comparison to the cost of developing the drug.”

Before the law, FDA approved roughly two drugs a year for rare diseases, according to a 2023 study by staff of FDA's Office of Orphan Products Development². In the law's first 40 years, through 2022, the agency granted 6,340 orphan drug designations covering 1,079 rare diseases, and 882 of those designations led to at least one approval. In 2025, half of the novel drugs approved by FDA's drug center (23 of 46) carried orphan designation, the agency's annual new drug report³ shows.

Today the act sits underneath a large share of new drug development, and it reaches the generic market in a specific way, through a seven-year exclusivity that can block copies for a protected use regardless of patents. This history covers how the 1983 law was built, how Congress reshaped it, what its incentives are worth today and what FDA's own counts show.

What the 1983 law contained

Congress built the act as a new subchapter of the Food, Drug, and Cosmetic Act with three main tools. A sponsor could ask FDA for written recommendations on the studies a rare-disease drug would need. A sponsor could ask FDA to “designate” a drug for a rare disease or condition. And once FDA approved a designated drug, the agency could not approve the same drug for the same disease from another company for seven years.

That seven-year protection, in the 1983 text¹, covered only a drug “for which a United States Letter of Patent may not be issued.” Patentable drugs were expected to rely on their patents. The law also created a federal tax credit equal to 50 percent of qualified clinical testing expenses, authorized $4 million a year in grants for fiscal 1983 through 1985 to help pay for clinical testing, and set up an Orphan Products Board inside the Department of Health and Human Services.

At first, the definition of a rare disease was purely economic. A condition qualified if it occurred “so infrequently in the United States that there is no reasonable expectation that the cost of developing and making available” a drug for it would be recovered from US sales. FDA's history of food and drug law¹⁰ sums up the purpose as “enabling FDA to promote research and marketing of drugs needed for treating rare diseases.”

The amendments that shaped the program

Within three years Congress rewrote two of the law's core pieces. The 200,000-person threshold that defines a rare disease today was added in 1984, and exclusivity was opened to patentable drugs in 1985. Later changes tightened when designation can be requested, cut the tax credit and wrote FDA's “clinical superiority” standard into the statute.

Each row comes from the amendment notes to 21 U.S.C. 360bb⁴ (designation), 21 U.S.C. 360cc⁵ (exclusivity) and 26 U.S.C. 45C⁶ (the tax credit). Under the 2017 change, “clinically superior” means a drug offers “a significant therapeutic advantage” through greater efficacy, greater safety, or “a major contribution to patient care.”

What designation is worth today

FDA's designation page⁷ lists three incentives: tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. The credit now stands at 25 percent of qualified clinical testing costs under section 45C⁶ of the tax code. Designation is a separate step from approval, and FDA says designated drugs go through “the same rigorous scientific review process as any other drug.”

A sponsor that asks to designate the same drug for the same rare disease as an earlier product “must submit their own data and information,” the agency says. Designation also survives growth in the patient count. FDA's rules at 21 CFR 316.29¹² say a designation granted because prevalence was under 200,000 will not be revoked if prevalence later rises above that line.

In 2026 the orphan label picked up a trade benefit as well. Proclamation 11020¹¹, which set tariffs of up to 100 percent on imported patented drugs (background in our piece on pharmaceutical tariffs), set a zero rate for drugs “where all approved indications are designated as orphan,” provided the product comes from a country with a qualifying trade agreement or meets an urgent US health need.

Where generics run into orphan exclusivity

Orphan exclusivity under section 360cc⁵ bars FDA from approving “another application under section 355” for the same drug and disease during the seven years. Section 355 includes the abbreviated new drug applications that generics use, so a generic version cannot be approved for an indication that orphan exclusivity protects, whatever the patent picture looks like. Our explainer on orphan drug exclusivity and the generics it blocks walks through examples. The clock runs separately from the patent listings and other exclusivities described in GxRadar's guides to the Orange Book and the Hatch-Waxman Act, which Congress passed the following year.

The protection is tied to the use. FDA's regulation at 21 CFR 316.31⁸ says exclusive approval “protects only the approved indication or use of a designated drug.” A generic can therefore sometimes reach the market for an older, unprotected indication while leaving the orphan use off its label, the approach covered in GxRadar's explainer on labeling carve-outs.

FDA can also approve a competing version early under the statute if the exclusivity holder cannot supply enough of the drug to meet patients' needs, or if the holder consents in writing. Small patient populations can mean thin generic interest even after exclusivity ends, one reason some older drugs have only one maker. FDA runs a separate program for drugs with too little generic competition, described in GxRadar's piece on competitive generic therapy.

What FDA's counts show after four decades

Designations grew sharply over time. In the 2023 FDA staff analysis², designations in 2013 through 2022 ran nearly seven times the number in 1983 through 1992, and initial approvals about six times. Only 14 percent of designations had led to an approval. Cancer dominated. Seven of the 10 most designated and approved diseases were rare cancers, and pancreatic cancer alone drew 185 designations.

Its authors put the reach of the program in perspective. With an estimated 7,000 to 10,000 described rare diseases, they concluded that “around 5% of rare diseases have an FDA-approved drug and up to 15%” have at least one drug that has shown promise. They also estimated that rare diseases affect more than 30 million Americans.

FDA's 2006 retrospective, Promoting Safe and Effective Drugs for 100 Years⁹, listed sickle cell anemia, cystic fibrosis and T-cell lymphoma as examples of rare conditions that orphan products had been developed to treat. The most recent annual figure, from the agency's 2025 report³, is 23 orphan-designated novel approvals in a single year, with a footnote that “not all drugs for rare diseases receive orphan drug designation.” FDA published that report in January 2026, and the 2026 tally will arrive in the next edition.